Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) Short Interest Up 99.8% in June

Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) saw a large increase in short interest during the month of June. As of June 30th, there was short interest totaling 35,280 shares, an increase of 99.8% from the June 15th total of 17,654 shares. Based on an average trading volume of 103,592 shares, the days-to-cover ratio is presently 0.3 days. Currently, 0.0% of the company’s shares are short sold.

Wall Street Analysts Forecast Growth

Separately, Zacks Research upgraded shares of Otsuka from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 31st. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold”.

Otsuka Price Performance

Shares of OTCMKTS:OTSKY opened at $34.04 on Friday. The company has a market capitalization of $36.57 billion and a PE ratio of 14.36. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.67 and a current ratio of 2.17. The stock has a fifty day moving average of $34.42 and a 200-day moving average of $33.12. Otsuka has a one year low of $21.68 and a one year high of $37.52.

Otsuka (OTCMKTS:OTSKY) last issued its earnings results on Tuesday, April 28th. The company reported $0.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.43 by $0.16. Otsuka had a return on equity of 12.33% and a net margin of 15.01%.The business had revenue of $3.96 billion for the quarter, compared to analysts’ expectations of $3.78 billion. Otsuka has set its FY 2026 guidance at 1.610-1.610 EPS. As a group, equities analysts anticipate that Otsuka will post 1.98 EPS for the current fiscal year.

About Otsuka

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.